• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Eye Center Warned for Failing to Submit IND for Combination Product Trial

Eye Center Warned for Failing to Submit IND for Combination Product Trial

December 5, 2022

The FDA has issued a warning letter to an eye center in Illinois for failing to file an investigational new drug application (IND) before initiating a trial of a combination drug-device investigational product.

The warning letter to David Lubeck of the Arbor Centers for EyeCare in Orland Park, dated Nov. 18, was sent following an FDA inspection in April which detailed “objectionable conditions” at the site, including a failure to submit an IND as required by regulations.

Specifically, the warning letter claims that Lubeck did not submit an IND to the FDA prior to starting the trial, which enrolled five participants, noting that his May 10 response to the agency’s Form 483 was insufficient.

In that response, Lubeck said that he and the institutional review board (IRB) determined that the trial protocol posed a nonsignificant risk to participants and that neither an IND nor an investigational device exemption were required.

The agency, however, noted that the investigational product has drug-device components and, therefore, must be regulated as a combination product requiring an IND, and that the FDA’s Center for Drug Evaluation and Research has primary jurisdiction over the product, not the IRB.

The FDA acknowledged that Lubeck halted enrollment and study activities after the IRB informed him that an IND was needed after all, but the IND submitted to the agency and referenced in his response did not contain the correct study protocol, instead featuring “a similar but substantively unique clinical protocol.”

The failure to have an IND approved before initiating the trial “raises concerns about the validity and integrity of data collected at your site during the conduct of the clinical investigation,” the agency said.

The Arbor Centers for EyeCare did not respond to a request for comment.

Read the FDA warning letter here: https://bit.ly/3Y4zM1N.

 

To view more CenterWatch Weekly stories, click here.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing